← Leaderboards
Nawajes Mandal
Miami Va Health Care System
$3,937,360
Attributed
$6,058,019
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,058,019 · 4
VA$0 · 1
By mechanism
R01$5,628,941 · 3
R21$429,078 · 1
I01$0 · 1
Top collaborators
- Dimitrios Karamichos8 shared
- Anat Galor5 shared
- Samuel Dagogo-Jack4 shared
Most similar at Miami Va Health Care System
Same institution · by research overlap
- Anat Galor$5,090,341
Others in their field
Top investigators on “Sphingosine 1-Phosphate”
- Timothy Tun Hla · Boston Children'S Hospital$24,167,600
- Julie D Saba · University Of California, San Francisco$13,164,302
- Sarah Spiegel · Virginia Commonwealth University$12,339,067
- Viswanathan Natarajan · Johns Hopkins University$11,430,603
- Kevin R Lynch · University Of Virginia$9,131,465
- Susan Ruth Schwab · New York University School Of Medicine$8,753,211
Research focus
Sphingosine 1-PhosphateSphingolipidsCeramidesSignal TransductionPathway InteractionsMediatingMetabolismAffectIn Vitro ModelMigrationBlindnessTherapeutic DevelopmentBaseInflammationIn VivoAreaSphingosine-1-Phosphate ReceptorComplexHuman DiseaseMediator Of Activation ProteinIn VitroPreventKnockout MiceFeedback
Grant awards (23)
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction$0
I01 · FY2025 · VA
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia$438,755
R01 · FY2024 · DK
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction$0
I01 · FY2024 · VA
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia$505,964
R01 · FY2023 · DK
Sphingolipids and their Impact in Corneal Wound Healing$405,358
R01 · FY2023 · EY · contact PI
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction$0
I01 · FY2023 · VA
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia$504,642
R01 · FY2022 · DK
Sphingolipids and their Impact in Corneal Wound Healing$393,197
R01 · FY2022 · EY · contact PI
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction$0
I01 · FY2022 · VA
Ceramides and Sphingolipids as Predictors of Incident Dysglycemia$530,534
R01 · FY2021 · DK
Sphingolipids and their Impact in Corneal Wound Healing$392,549
R01 · FY2021 · EY · contact PI
Dietary Supplement of n-3 PUFA to Control Corneal Inflammation$153,052
R01 · FY2021 · EY · contact PI
Sphingolipids and their Impact in Corneal Wound Healing$61,505
R01 · FY2021 · EY · contact PI
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunction$0
I01 · FY2021 · VA
Sphingolipids and their Impact in Corneal Wound Healing$426,685
R01 · FY2020 · EY · contact PI
Sphingolipid Metabolism and Signaling in the Retina$251,268
R01 · FY2016 · EY · contact PI
Sphingolipid signaling in corneal wound healing and fibrosis$192,315
R21 · FY2016 · EY
Sphingolipid Metabolism and Signaling in the Retina$118,732
R01 · FY2016 · EY · contact PI
Sphingolipid Metabolism and Signaling in the Retina$362,600
R01 · FY2015 · EY · contact PI
Sphingolipid signaling in corneal wound healing and fibrosis$236,763
R21 · FY2015 · EY
Sphingolipid Metabolism and Signaling in the Retina$362,600
R01 · FY2014 · EY · contact PI
Sphingolipid Metabolism and Signaling in the Retina$351,500
R01 · FY2013 · EY · contact PI
Sphingolipid Metabolism and Signaling in the Retina$370,000
R01 · FY2012 · EY · contact PI